Wellgistics Health

WGRX

Market cap $17M

TAMPA, FL / ACCESS Newswire / March 13, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics"), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced that its President & Interim-CEO Prashant Patel, RPh released a letter to shareholders. The prescription drug and broader healthcare landscapes in the United States are rapidly changing.

Medical insurance eligibility and benefits verification (EBV) is a core health technology capability necessary for PharmacyChain™ to gain market adoption EBV services offering enabled with preferred pricing being made immediately available to providers, partners and the Wellgistics Pharmacy Network EBV market expected to grow from $2.39 billion in 2025 to $3 billion in 2030 according to The Business Research Company1 TAMPA, FL / ACCESS Newswire / March 11, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics"), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced that it has secured contractual rights to preferred pricing for medical insurance eligibility and benefits verification (EBV) that enables PharmacyChain for providers, partners and pharmacies in order to facilitate its faster adoption into the US healthcare ecosystem. EBV is crucial because it allows companies that engage in the distribution of medical products and services to know whether a particular product or service is covered by a patient's insurance carrier and the level of coverage that patient has.

GLP-1 agonist market expected to grow from $70B in 2025 to $201B in 20301 Proprietary Forzet formulation provides pharmacists, physicians and patients with unique solution for GLP-1 drugs' primary side effect Forzet targeting preservation of muscle while on GLP-1 agonist therapy to facilitate continued patient adherence and muscle redevelopment following therapy discontinuation to help mitigate weight regain   TAMPA, FLORIDA / ACCESS Newswire / March 9, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics") , a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ , today announced the launch of medical food Forzet™ for the dietary management of muscle loss associated with weight loss therapies. Forzet is being launched initially to physicians and pharmacists who prescribe and dispense GLP-1 agonist drugs.

Hyperledger Fabric, Ethereum/Polygon, VeChain, Quorum /Besu and Corda (R3) selected as most suitable blockchain platforms to build PharmacyChain™ U.S. prescription drugs market project to grow from $634 billion market to $883 billion by 2030 according to Grandview Research[1] Global blockchain in healthcare market is projected to grow from $11 billion in 2024 to $214 billion by 2030, according to Grandview Research[2] TAMPA, FLORIDA / ACCESS Newswire / March 5, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics"), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ , today announced that it has completed its evaluation process to select the most suitable blockchain platforms on which to build smart contracts-enabled pharmaceutical drug tracking system PharmacyChain that will further enable industry-wide serialization mandates, such as the United States' Drug Supply Chain Security Act (DSCSA[3]). The Company selected Hyperledger Fabric, Ethereum/Polygon, VeChain, Quorum/Besu and Corda (R3) as the most suitable blockchain platforms currently in use in order to initiate PharmacyChain development.

Previously announced partnership with Tollo Health subsidiary TolloCare adding telehealth service offering to drive Wellgistics Pharmacy prescription drug dispending of GLP-1 drugs and promote patient engagement via mental health AI software solution for compliance and to promote lifestyle changes TAMPA, FL / ACCESS Newswire / February 18, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (‘AI') platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ , today announced that it has completed a strategic investment in a San Francisco-based mental health AI startup on the cusp of launching its service following successful beta testing. The investment fortifies the Company's strategic partnership with Tollo Health that was expanded to support Wellgistics' partnership with NFL Alumni Health.

Tollo Health recently formed subsidiary TolloCare, LLC ('TolloCare') initially targeted to provide telehealth services for GLP-1 and Long COVID patients TolloCare has white-labeled telehealth capabilities via a telemedicine company with over 5,000 onboarded physicians nationwide to provide synchronous and asynchronous medical services, including prescriptions, for weight loss and separately will cultivate a Long COVD physician base Tollo Health has entered into agreement to expand TolloCare capabilities via a partnership with a stealth San Francisco Bay Area startup preparing to deploy a mental health AI app with unique tools to engage with patients TAMPA, FLORIDA / ACCESS Newswire / February 11, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence ('AI') platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ , today announced that it has expanded its partnership Tollo Health, LLC ('Tollo Health'). The partnership expansion includes the addition of telehealth services being developed by TolloCare, LLC ('TolloCare'), a wholly-owned subsidiary of Tollo Health, which focuses on telemedicine, an app-based mental health AI offering, and public health information.

Feasibility assessment completed, PharmacyChain™ to leverage Datavault AI's edge network and quantum key encryption to improve data driven outcomes in $634 billion prescription drug market Quantum key encryption fortities pharmacies from quantum's pending encryption-busting impact on traditional encryption methods TAMPA, FLORIDA / ACCESS Newswire / January 12, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (‘AI') platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today provided an update on its strategic licensing partnership with DataVault AI, Inc. (NASDAQ:DVLT), a Pioneer in AI-driven data valuation, monetization, and secure tokenization within Web 3.0 environments. Through this partnership, Wellgistics has licensed DataVault AI's advanced technology platform to integrate proprietary blockchain-enabled tokenization and blockchain-enabled smart contract capabilities into its patented PharmacyChain™ platform.

Integration of prescription drug dispensing optimization aritifical intelligence platform EinsteinRx™ into pharmacy client point-of-sales systems has commenced EinsteinRx integration streamlining effort focuses on reducing onboarding process friction and speeding time to implementation prior to scaling pharmacy marketing effort Company expects to onboard up to 500 pharmacies per month into formal Wellgistics Pharmacy Network by year end 2026 Manufacturer supplier relationship expansion effort focused on diabetes, weight loss, cardiometabolic & Long COVID patients that existing pharmacy clients already serve PharmacyChain™ blockchain-enabled healthcare smart contract development resource assessment ongoing TAMPA, FLORIDA / ACCESS Newswire / January 7, 2026 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (‘AI') platform EinsteinRx ™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today provided a corporate outlook for 2026 to stakeholders. "Three months following my return to the role of President at Wellgistics, the Company now has a clear direction as we begin a hyper-focused operational execution phase," said Prashant Patel, RPh, President & Interim-CEO of Wellgistics Health.

TAMPA, FL / ACCESS Newswire / December 17, 2025 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx ™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today reminded shareholders of the December 19, 2025 record date (the "Record Date") to receive Dream Bowl 2026 Meme Coin ("Dream Bowl") tokens. All eligible record holders of Wellgistics Health, Inc. common stock will receive one (1) Dream Bowl token for every one (1) share of common stock owned.

Launch targets $16 billion SGLT-2 inhibitor market that serves 33 million type II diabetics in the US, many of whom are uninsured and underinsured and whose out-of-pocket costs exceed Brenzavvy's cash price Proprietary EinsteinRx™ artificial intelligence pharmacy platform empowers the 6,500+ pharmacies in the Wellgistics Pharmacy Network to educate patients and providers on the advantages of Brenzavvy vs. Jardiance® and other SGLT-2 inhibitors Reduced out-of-pocket costs for patients, paired with a patient-education revenue opportunity for pharmacists, are designed to support broader market access to Brenzavvy and enhance the overall care experience Launch establishes a new model for next-generation reformulated drugs that offer patient-specific product advantages compared with entrenched market leaders TAMPA, FL / ACCESS Newswire / December 8, 2025 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx ™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced that it has begun the commercial launch of diabetes prescription drug Brenzavvy® to its network of 6,500 independent pharmacies (the "Wellgistics Pharmacy Network") that primarily target patients in rural communities where there is often an increased incidence of diabetes.